Coencapsulation of alendronate and doxorubicin in pegylated liposomes: a novel formulation for chemoimmunotherapy of cancer

Using solution X-ray scattering to determine the high-resolution structure and morphology of PEGylated liposomal doxorubicin nanodrugs

(2016) Y. Schilt et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

Novel Pullulan Bioconjugate for Selective Breast Cancer Bone Metastases Treatment

(2015) Gwénaëlle Bonzi et al.   BIOCONJUGATE CHEMISTRY

Denosumab and fracture risk in women with breast cancer

(2015) Robert Coleman et al.   LANCET

In vitro experiments showing enhanced release of doxorubicin from Doxil® in the presence of ammonia may explain drug release at tumor site

(2015) Lisa Silverman et al.   Nanomedicine-Nanotechnology Biology and Medicine

Liposome promotion of tumor growth is associated with angiogenesis and inhibition of antitumor immune responses

(2015) Manoj K. Sabnani et al.   Nanomedicine-Nanotechnology Biology and Medicine

Adoptive Immunotherapy of Epithelial Ovarian Cancer with Vγ9Vδ2 T Cells, Potentiated by Liposomal Alendronic Acid

(2014) Ana C. Parente-Pereira et al.   JOURNAL OF IMMUNOLOGY

Complement activation-related pseudoallergy: A stress reaction in blood triggered by nanomedicines and biologicals

(2014) Janos Szebeni   MOLECULAR IMMUNOLOGY

Liposome encapsulation of zoledronic acid results in major changes in tissue distribution and increase in toxicity

(2013) Hilary Shmeeda et al.   JOURNAL OF CONTROLLED RELEASE

Macrophages as potential targets for zoledronic acid outside the skeleton—evidence from in vitro and in vivo models

(2013) T. L. Rogers et al.   CELLULAR ONCOLOGY

The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo

(2012) Hiroshi Maeda et al.   ADVANCED DRUG DELIVERY REVIEWS

Potential Anticancer Properties of Bisphosphonates: Insights From Preclinical Studies

(2012) Philippe Clezardin   Anti-Cancer Agents in Medicinal Chemistry

Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer

(2012) Sanjay I. Thamake et al.   BIOMATERIALS

Cutting Edge: Nitrogen Bisphosphonate-Induced Inflammation Is Dependent upon Mast Cells and IL-1

(2012) J. T. Norton et al.   JOURNAL OF IMMUNOLOGY

Effects of Bone-Targeted Agents on Cancer Progression and Mortality

(2012) R. Coleman et al.   JNCI-Journal of the National Cancer Institute

Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: Prediction and prevention

(2011) Janos Szebeni et al.   ADVANCED DRUG DELIVERY REVIEWS

Combination therapy inhibits development and progression of mammary tumours in immunocompetent mice

(2011) Penelope D. Ottewell et al.   BREAST CANCER RESEARCH AND TREATMENT

High Phosphoantigen Levels in Bisphosphonate-Treated Human Breast Tumors Promote V 9V 2 T-Cell Chemotaxis and Cytotoxicity In Vivo

(2011) I. Benzaid et al.   CANCER RESEARCH

Liposomal alendronate for the treatment of restenosis

(2011) Dikla Gutman et al.   JOURNAL OF CONTROLLED RELEASE

Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: Studies with human gastro-entero-pancreatic ectopic tumor models

(2011) Alberto Gabizon et al.   JOURNAL OF CONTROLLED RELEASE

Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes

(2011) Monica Marra et al.   Nanomedicine-Nanotechnology Biology and Medicine

Bisphosphonates' antitumor activity: An unravelled side of a multifaceted drug class

(2010) Philippe Clézardin   BONE

Delivery of zoledronic acid encapsulated in folate-targeted liposome results in potent in vitro cytotoxic activity on tumor cells

(2010) Hilary Shmeeda et al.   JOURNAL OF CONTROLLED RELEASE

Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model

(2009) Penelope D. Ottewell et al.   INTERNATIONAL JOURNAL OF CANCER

Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer

(2009) Michael Gnant et al.   NEW ENGLAND JOURNAL OF MEDICINE